Breakthrough Cancer Pain: Ten Commandments

Portenoy, 1990, Breakthrough pain: definition, prevalence and characteristics, Pain, 41, 273, 10.1016/0304-3959(90)90004-W Daut, 1983, Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases, Pain, 17, 197, 10.1016/0304-3959(83)90143-4 Cleeland CS. Assessment of pain in cancer: measurement issues. In: Foley KM, Bonica JJ, Ventafridda V, eds, Proceedings of the Second International Congress on Cancer Pain. Advances in Pain Research and Therapy (Vol. 16). New York, NY: Raven Press, 1990:47–55. Hanks, 2001, Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations, Br J Cancer, 84, 587, 10.1054/bjoc.2001.1680 Portenoy, 1999, Breakthrough pain: characteristics and impact in patients with cancer pain, Pain, 81, 129, 10.1016/S0304-3959(99)00006-8 Serlin, 1995, When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function, Pain, 61, 277, 10.1016/0304-3959(94)00178-H Deandrea, 2014, Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature, J Pain Symptom Manage, 47, 57, 10.1016/j.jpainsymman.2013.02.015 Mercadante, 2004, Optimization of opioid therapy for preventing incident pain associated with bone metastases, J Pain Symptom Manage, 28, 505, 10.1016/j.jpainsymman.2004.02.024 Mercadante, 2013, Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies, Curr Med Res Opin, 29, 667, 10.1185/03007995.2013.792247 Davies, 2009, The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, Eur J Pain, 13, 331, 10.1016/j.ejpain.2008.06.014 Mercadante, 2013, Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients, Curr Med Res Opin, 29, 93, 10.1185/03007995.2012.755120 Bennett, 2005, Consensus panel recommendations for the assessment and management of breakthrough pain, part 2: management, Pharm Ther, 30, 354 Gómez-Batiste, 2002, Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain, J Pain Symptom Manage, 24, 45, 10.1016/S0885-3924(02)00421-9 Greco, 2011, Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group, Clin J Pain, 27, 9, 10.1097/AJP.0b013e3181edc250 Caraceni, 2012, Episodic (breakthrough) pain prevalence in a population of cancer pain patients: comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain, J Pain Symptom Manage, 43, 833, 10.1016/j.jpainsymman.2011.05.018 Caraceni, 2004, Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey, Palliat Med, 18, 177, 10.1191/0269216304pm890oa Petzke, 1999, Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic, J Pain Symptom Manage, 17, 391, 10.1016/S0885-3924(99)00023-8 Svendsen, 2005, Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms, Eur J Pain, 9, 195, 10.1016/j.ejpain.2004.06.001 Swanwick, 2001, The prevalence of episodic pain in cancer: a survey of hospice patients on admission, Palliat Med, 15, 9, 10.1191/026921601668030190 Zeppetella, 2000, Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice, J Pain Symptom Manage, 20, 87, 10.1016/S0885-3924(00)00161-5 Mercadante, 2010, Breakthrough pain in oncology: a longitudinal study, J Pain Symptom Manage, 40, 183, 10.1016/j.jpainsymman.2010.01.010 Mercadante, 2009, Breakthrough pain in advanced cancer patients followed at home: a longitudinal study, J Pain Symptom Manage, 38, 554, 10.1016/j.jpainsymman.2008.12.008 Mercadante, 2015, IOPS Study Group Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings, Clin J Pain, 31, 214, 10.1097/AJP.0000000000000161 Davies, 2013, Breakthrough cancer pain: an observational study of 1000 European oncology patients, J Pain Symptom Manage, 46, 619, 10.1016/j.jpainsymman.2012.12.009 Mercadante, 2014, Breakthrough pain in patients with abdominal cancer pain, Clin J Pain, 30, 510, 10.1097/AJP.0000000000000004 Haugen, 2010, Assessment and classification of cancer breakthrough pain: a systematic literature review, Pain, 149, 476, 10.1016/j.pain.2010.02.035 Hagen, 2008, The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi process and patient think-aloud interviews, J Pain Symptom Manage, 35, 136, 10.1016/j.jpainsymman.2007.03.016 Webber, 2014, Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients, J Pain Symptom Manage, 48, 619, 10.1016/j.jpainsymman.2013.10.026 Mercadante, 2012, Pharmacotherapy for breakthrough cancer pain, Drugs, 72, 181, 10.2165/11597260-000000000-00000 Coluzzi, 2001, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR), Pain, 91, 123, 10.1016/S0304-3959(00)00427-9 Christie, 1998, Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain, J Clin Oncol, 16, 3238, 10.1200/JCO.1998.16.10.3238 Davies, 2011, Consistency of efficacy, patients acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate in breakthrough cancer pain, J Pain Symptom Manage, 41, 358, 10.1016/j.jpainsymman.2010.11.004 Farrar, 1998, Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients, J Natl Cancer Inst, 90, 611, 10.1093/jnci/90.8.611 Kress, 2009, Efficacy and tolerability of intranasal spray 50 to 200µg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trail with a 10-month, open-label extension treatment period, Clin Ther, 31, 1177, 10.1016/j.clinthera.2009.05.022 Lennernas, 2010, Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study, Palliat Med, 24, 286, 10.1177/0269216309356138 Portenoy, 1999, Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study, Pain, 79, 303, 10.1016/S0304-3959(98)00179-1 Portenoy, 2006, A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer, Clin J Pain, 22, 805, 10.1097/01.ajp.0000210932.27945.4a Portenoy, 2010, A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain, Pain, 151, 617, 10.1016/j.pain.2010.07.028 Rauck, 2010, Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study, Ann Oncol, 21, 1308, 10.1093/annonc/mdp541 Slatkin, 2007, Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain, J Support Oncol, 5, 327 National Institute for Health and Care Excellence. Palliative care for adults: strong opioids for pain relief. 2012. Available from: www.nice.org.uk/cg140. [Accessed May 1, 2014]. Zeppetella, 2009, Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management, Eur J Cancer Care, 18, 331, 10.1111/j.1365-2354.2008.01009.x Mercadante, 2009, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial, Curr Med Res Opin, 25, 2805, 10.1185/03007990903336135 Mercadante, 2014, Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen, J Pain, 15, 602, 10.1016/j.jpain.2014.02.002 England, 2011, How practical are transmucosal fentanyl products for breakthrough cancer pain? A survey of user opinion, BMJ Support Palliat Care, 1, 349, 10.1136/bmjspcare-2011-000037 Mercadante, 2014, Patients’ acceptability of different fentanyl products for breakthrough cancer pain, Clin Oncol (R Coll Radiol), 26, 806, 10.1016/j.clon.2014.09.003 Mercadante, 2015, Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options, Curr Opin Anaesthesiol, 28, 559, 10.1097/ACO.0000000000000224 Mercadante, 2009, Breakthrough pain: on the road again, Eur J Pain, 13, 329, 10.1016/j.ejpain.2008.11.021 Mercadante, 2011, The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing, Crit Rev Oncol Hematol, 80, 460, 10.1016/j.critrevonc.2010.12.002 Mercadante, 2011, Rapid onset opioids for breakthrough pain: titrating or not titrating, this is the question, Eur J Pain Suppl, 5, 443, 10.1016/j.eujps.2011.08.044 Davies, 2008, An observational study of oncology patients’ utilization of breakthrough pain medication, J Pain Symptom Manage, 35, 406, 10.1016/j.jpainsymman.2007.05.010 Hagen, 2007, A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials, J Palliat Med, 10, 47, 10.1089/jpm.2006.0151 Mercadante, 2012, Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses, Curr Med Res Opin, 28, 963, 10.1185/03007995.2012.683112 Mercadante, 2004, Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose, J Pain Symptom Manage, 27, 352, 10.1016/j.jpainsymman.2003.09.006 Mercadante, 2010, Intravenous morphine for management of cancer pain, Lancet Oncol, 11, 484, 10.1016/S1470-2045(09)70350-X Mercadante, 2010, The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen, Clin J Pain, 26, 306, 10.1097/AJP.0b013e3181c4458a Mercadante, 2007, Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain, Br J Cancer, 96, 1828, 10.1038/sj.bjc.6603811 Mercadante, 2006, Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine, J Pain Symptom Manage, 32, 175, 10.1016/j.jpainsymman.2006.01.013 Mercadante, 2008, Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study, J Pain Symptom Manage, 35, 307, 10.1016/j.jpainsymman.2007.04.018 Mercadante, 2011, Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose, J Pain Symptom Manage, 42, 464, 10.1016/j.jpainsymman.2010.12.010 Mercadante, 2013, The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen, Curr Med Res Opin, 29, 1527, 10.1185/03007995.2013.826640 Mercadante, 2015, Fentanyl buccal tablet versus oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study, J Pain Symptom Manage, 50, 579, 10.1016/j.jpainsymman.2015.05.016 Zeppetella, 2008, Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief, J Pain Symptom Manage, 35, 563, 10.1016/j.jpainsymman.2007.06.012